TFF2 and ischemic stroke: Given the clear increase in SP that has been documented in both experimental and clinical stroke studies, NK1 tachykinin receptor antagonists have been investigated for their potential utility in reducing BBB dysfunction and vasogenic edema in the setting of ischemic stroke.